ReviewHealthcare (Basel, Switzerland)2025
The Relevance of Chronological and Biological Aging in the Progression of Multiple Sclerosis.
Review in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteomic Age Acceleration in Multiple Sclerosis Precedes Symptom Onset and Associates with Severity.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronological age (C-Age), determined by the time elapsed since the birth of an individual, is considered one of the main risk factors for the onset and prognosis of multiple sclerosis (MS). Biological age (B-Age), in contrast, conditioned by genetic, lifestyle, comorbidity, and environmental factors, defines the aging of tissues that contributes to the decline of organ function, the loss of functional reserve, and decrease in the regenerative capacity. In this context immunosenescence is increasingly evidenced as a factor that contributes to the MS progressive course and loss of efficacy of MS drugs. B-Age can be estimated through different measurement strategies such as telomere length, epigenetic clocks and biomarker composites. These biomarkers are gaining attention in MS research since they seem to be associated with disability progression and are modulated by lifestyle interventions. This review summarizes the roles of C-Age and B-Age in MS and highlights implications for prognosis and therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.